Health Insurance to cover Elaprase and Naglazyme

Published: 2008-12-26 06:59:00

Updated: 2008-12-26 06:59:00

Those who have suffered from Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis VI (MPS VI) will be covered by health insurance, the Ministry of Health, Welfare and Family Affairs said on December 22.

Elaprase is the first and only enzyme replacement therapy approved for people suffer...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK